Emergent Biosolutions Pre-Tax Profit Margin 2007-2021 | EBS

Emergent Biosolutions pre-tax profit margin from 2007 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Emergent Biosolutions Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2021-09-30 $1.65B $0.30B 18.09%
2021-06-30 $1.71B $0.40B 23.41%
2021-03-31 $1.71B $0.51B 30.13%
2020-12-31 $1.56B $0.41B 26.22%
2020-09-30 $1.33B $0.23B 16.95%
2020-06-30 $1.26B $0.23B 18.25%
2020-03-31 $1.11B $0.09B 8.48%
2019-12-31 $1.11B $0.08B 6.96%
2019-09-30 $1.02B $0.01B 0.98%
2019-06-30 $0.88B $-0.03B -3.07%
2019-03-31 $0.86B $0.05B 6.31%
2018-12-31 $0.78B $0.08B 10.60%
2018-09-30 $0.71B $0.13B 18.56%
2018-06-30 $0.68B $0.16B 22.76%
2018-03-31 $0.56B $0.10B 17.08%
2017-12-31 $0.56B $0.12B 21.21%
2017-09-30 $0.52B $0.12B 22.35%
2017-06-30 $0.51B $0.10B 20.27%
2017-03-31 $0.50B $0.09B 18.69%
2016-12-31 $0.49B $0.10B 20.45%
2016-09-30 $0.48B $0.14B 28.24%
2016-06-30 $0.49B $0.16B 33.06%
2016-03-31 $0.53B $0.19B 35.23%
2015-12-31 $0.49B $0.14B 27.81%
2015-09-30 $0.45B $0.13B 28.22%
2015-06-30 $0.43B $0.10B 22.09%
2015-03-31 $0.41B $0.08B 19.81%
2014-12-31 $0.40B $0.08B 20.79%
2014-09-30 $0.40B $0.03B 8.25%
2014-06-30 $0.35B $0.02B 5.98%
2014-03-31 $0.32B $0.03B 8.98%
2013-12-31 $0.31B $0.04B 14.10%
2013-09-30 $0.31B $0.04B 14.24%
2013-06-30 $0.29B $0.04B 12.54%
2013-03-31 $0.28B $0.03B 11.27%
2012-12-31 $0.28B $0.03B 11.35%
2012-09-30 $0.30B $0.05B 18.31%
2012-06-30 $0.29B $0.05B 15.68%
2012-03-31 $0.31B $0.06B 18.03%
2011-12-31 $0.27B $0.03B 11.68%
2011-09-30 $0.27B $0.02B 7.81%
2011-06-30 $0.28B $0.04B 14.08%
2011-03-31 $0.26B $0.04B 13.57%
2010-12-31 $0.29B $0.07B 25.87%
2010-09-30 $0.24B $0.04B 18.14%
2010-06-30 $0.21B $0.02B 9.22%
2010-03-31 $0.22B $0.03B 12.44%
2009-12-31 $0.24B $0.04B 17.45%
2009-09-30 $0.22B $0.04B 17.51%
2009-06-30 $0.23B $0.06B 25.11%
2009-03-31 $0.20B $0.04B 18.91%
2008-12-31 $0.18B $0.03B 17.88%
2008-09-30 $0.23B $0.08B 32.19%
2008-06-30 $0.22B $0.06B 29.09%
2008-03-31 $0.20B $0.05B 26.50%
2007-12-31 $0.18B $0.04B 19.67%
2007-09-30 $0.18B $0.04B 20.00%
2007-06-30 $0.18B $0.04B 22.47%
2007-03-31 $0.17B $0.04B 25.30%
2006-12-31 $0.15B $0.04B 25.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.380B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88